EGFR and non-small cell lung carcinoma: Compared with gefitinib, aumolertinib and furmonertinib both also had longer median PFS (19.3 months vs. 9.9 months and 20.8 months vs. 11.1 months, respectively) as the first-line treatment for EGFR-mutated NSCLC in the AENEAS and FURLONG phase 3 studies, with an acceptable safety profile [47, 48].